N/A
Completed N=15
BEAST: A Pilot Trial
Anxiety Sensitivity · functional impairment
Source: ClinicalTrials.gov NCT05416203 ↗
Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Mean Change in Anxiety Sensitivity — -11.15 score on a scale
Summary
This pilot study trial will test the acceptability, feasibility, and usability of a brief enhanced anxiety sensitivity treatment to reduce anxiety sensitivity and functional impairment in Veterans.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change in Anxiety Sensitivity |
-11.15 | — |
| PRIMARY Program Satisfaction |
3.95 | — |
| PRIMARY Mean Change in Functional Impairment |
-7.38 | — |
| SECONDARY Mean Changes in Anxiety |
-6.62 | — |
| SECONDARY Mean Changes in Worry Related to the COVID-19 Pandemic |
-9.67 | — |
| SECONDARY Mean Changes in Avoidance Due to the COVID-19 Pandemic |
-.15 | — |
| SECONDARY Mean Changes in Functional Impairment Due to the COVID-19 Pandemic |
-1.58 | — |
| SECONDARY Mean Change in Depression |
-2.92 | — |
Eligibility Criteria
Inclusion Criteria
- Are English-speaking
- Score equal to or greater than 9 on the SSASI indicating elevated anxiety sensitivity
- Score equal to or greater than 5 on the WHODAS 2.0
Exclusion Criteria
- Veterans with cognitive impairment as measured scoring equal to or greater than 11 on the Blessed
- Orientation-Memory-Concentration Test
- Veterans without access to a smartphone
- Veterans with significant medical or psychiatric conditions that may limit participation, including:
- severe documented schizophrenia
- an ongoing active psychotic or manic state
- an imminent suicide crisis will be excluded from our study and provided the appropriate referral
Data sourced from ClinicalTrials.gov (NCT05416203). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.